Eric Y Fang

Title: Eric Y Fang: Innovator in GSK3 Polypeptides

Introduction

Eric Y Fang is a notable inventor based in Oakland, CA. He has made significant contributions to the field of biochemistry, particularly in the development of GSK3 polypeptides. With a total of 6 patents, his work focuses on innovative solutions for treating diseases related to GSK3 activity.

Latest Patents

One of Eric's latest patents involves truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides. This invention provides methods to identify and optimize GSK3 inhibitors. Additionally, it includes GSK3 polypeptides with at least one substituted amino acid that differs from wild-type GSK3, where the substituted amino acid is incapable of being phosphorylated. The invention is particularly useful for developing compounds that can treat diseases mediated by GSK3 activity, such as Alzheimer's disease, type 2 diabetes, and inflammation.

Career Highlights

Throughout his career, Eric has worked with prominent companies in the biotechnology sector. He has been associated with Chiron Corporation and Novartis Vaccines & Diagnostics GmbH, where he contributed to various innovative projects. His expertise in the field has allowed him to make substantial advancements in biopharmaceuticals.

Collaborations

Eric has collaborated with notable professionals in his field, including Stephen David Harrison and John Andrew Hall. These collaborations have further enhanced his research and development efforts.

Conclusion

Eric Y Fang is a distinguished inventor whose work on GSK3 polypeptides has the potential to impact the treatment of several significant diseases. His contributions to the field of biochemistry continue to pave the way for innovative therapeutic solutions.